Prognostic significance of postoperative loss of skeletal muscle mass in patients underwent coronary artery bypass grafting

Zi-Le Shen1, Zhang Liu2,†, Peng Zhang2, Wei-Zhe Chen1, Wen-Xi Dong3, Wen-Hao Chen3, Feng Lin1, Wang-Fu Zang2*, Xia-Lin Yan4*, and Zhen Yu1,3*

1Department of Gastrointestinal Surgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China, 2Department of Cardio-Thoracic Surgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China, 3Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, 4Department of Colorectal Anal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Background: Increasing life expectancy of coronary artery bypass grafting (CABG) remains to be the major concern of cardiac surgeons. However, few studies have investigated the effect of postoperative skeletal muscle index (SMI) loss on prognosis. This study aims to evaluate the prognostic role of postoperative SMI loss ≥ 5% after CABG, in order to develop a novel nomogram to predict overall survival (OS).

Methods: Patients underwent CABG via midline sternotomy from December 2015 to March 2021 were recruited in this study. Preoperative and postoperative 3 months chest computed tomography (CT) images were compared to assess changes in SMI at T12 level. Based on this, patients were classified into the presence or absence of SMI loss ≥ 5%. The association between postoperative SMI loss ≥ 5% and OS was then analyzed by the Kaplan-Meier curves and Cox model. A novel nomogram incorporating independent clinical prognostic variables was also developed.

Results: The study enrolled 506 patients receiving CABG, of whom 98 patients experienced T12 SMI loss ≥ 5% and had a significantly worse OS (P < 0.0001). Multivariate regression analysis showed that T12 SMI per cent change (%T12 SMI-change) was an independent prognostic factor for OS (HR = 0.809, 95% CI = 0.749–0.874). The nomogram incorporating %T12 SMI-change with other variables was accurate for predicting OS. Besides,
we also found that postoperative oral nutritional supplement (ONS) can rescue T12 SMI loss.

**Conclusion:** Postoperative SMI loss can predict survival outcome after CABG. The nomogram incorporating changes in SMI provides a superior performance than existing systems.

**KEYWORDS**
skeletal muscle loss, coronary artery bypass grafting, nomogram, survival, oral nutritional supplement

---

**Introduction**

Coronary artery disease (CAD) is a global burden in terms of high mortality, morbidity and economic loss (1, 2). As a preferred treatment for patients with 3-vessel disease and left main CAD, coronary artery bypass grafting (CABG) provides surgical collateralization and prolong life (3, 4). However, preventing postoperative complications and increasing life expectancy still arouse cardiac surgeons' concerns (5). Previous studies on improving the prognosis of patients underwent CABG have mainly focused on treatment-related factors, such as the selection of grafts, surgical approach methods, and the establishment of extracorporeal circulation (6–9). Conversely, some patient-related modifiable factors, such as postoperative weight loss, sarcopenia, etc., have not been studied extensively, and corresponding measures to improve these factors are lacking.

Measurement of body composition and its impact on outcomes after cardiac surgery are gaining increasing attention. Our study has previously confirmed that preoperative sarcopenia is associated with unfavorable short- and long-term prognosis of patients receiving CABG (10). Estimating preoperative skeletal muscle index (SMI) has a predictive effect and allows for timely therapeutic intervention for better postoperative outcomes. However, many patients underwent CABG experience muscle wasting during the recovery period, which results in reduced muscle mass, functional capacity and quality of life, and increased mortality, especially in patients older than 50 years (11, 12). Surgery-induced stress, inflammation, and protein depletion all contribute to disturbed metabolism and postoperative skeletal muscle loss (13, 14). Considering the dynamic change of SMI during perioperative period, it may inadequate to merely assess the state of skeletal muscle before surgery to predict the clinical outcomes of the patients and formulate postoperative rehabilitation programs. Nevertheless, the few existing studies mainly focused on the impact of preoperative skeletal muscle assessment on the prognosis of CABG patients (10, 15), and the relationship between postoperative skeletal muscle loss and clinical outcomes in these patients is unclear.

In this study, we explored the factors affecting SMI loss after CABG, and investigated the predictive role of postoperative SMI loss on long-term outcomes in CABG patients. The secondary objective was to develop a novel nomogram with body composition-related parameters for predicting overall survival (OS) and verify its predictive effect in patients underwent CABG.

**Materials and methods**

**Patient eligibility and data collection**

Between December 2015 and March 2021, patients aged ≥ 18 years who underwent CABG through midline sternotomy at the Department of Cardio-Thoracic Surgery, Shanghai Tenth People’s Hospital were recruited in this study. Patients with emergency surgery, a history of previous cardiothoracic surgery, insufficient chest computed tomography (CT) data, or in-hospital mortality were excluded. All the patients signed written informed consent. This study was conducted following the Helsinki Declaration of the World Medical Association, and the research approach was approved by the ethics committee of Shanghai Tenth People’s Hospital and registered in Chinese Clinical Trial Registry (ChiCTR2000037875).

For each patient, the following clinical data were collected by trained surgeons: (1) preoperative characteristics, including general information, cardiac function-related information, existing comorbidity, laboratory tests and nutritional risk assessment [evaluated by prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI)] during preoperative period; (2) operative features, including type of surgery, number of bypassed vessels, and operative time; (3) postoperative characteristics, including postoperative complications graded by Clavien-Dindo classification (16) (Grade ≥ II were analyzed), severe complications (Grade ≥ III) and the use of oral nutritional supplement (ONS). According to the doctor's recommendation, patients with reduced eating were prescribed with Ruineng® (Sino-Swed Pharmaceutical Corp. Ltd.) for 5 days after CABG. This ONS product is a nutritionally balanced enteral nutritional emulsion, containing approximately 650 kcal energy, 29.3 g protein, 36 g fat, 52 g of carbohydrate, and vitamins and minerals per 500 ml. Patients receiving the advice...
of physician took ONS after CABG, and the expected daily intake of ONS was 500 ml. And patients did not routinely receive exercise rehabilitation training after CABG.

Quantification of skeletal muscle mass

The chest CT images performed within 2 weeks before and 3 months after CABG were collected, respectively. Then we analyzed these collected images at the 12th thoracic vertebra (T12) level by INFINITT PACS software (version 3.0.11.3, Seoul, Korea) to identify skeletal muscle in the range of –29 to +150 Hounsfield unit (HU). Skeletal muscles evaluated at T12 level contained the rectus abdominis, external oblique, internal oblique, latissimus dorsi, intercostal, and erector spinae muscles. The skeletal muscle area was normalized by height \( (m^2) \) to determine the SMI \( (\text{cm}^2/m^2) \) at T12. Consistent with our previous study, referring to a large-scale study, low SMI was defined as T12 SMI < 28.8 cm²/m² for male and < 20.8 cm²/m² for female (10, 17). T12 SMI percent change (%T12 SMI-change) was calculated as (postoperative T12 SMI—preoperative T12 SMI)/preoperative T12 SMI \( \times 100\% \). Since multiple studies have demonstrated that SMI loss ≥ 5% is associated with adverse clinical outcomes (18–21), we used this threshold to divide patients into T12 SMI loss ≥ 5% and T12 SMI loss < 5% groups to compare OS according to SMI change in this study.

Follow-up

All patients were followed up every 3 months for the first 2 years, and every 6 months after that by telephone interviews or outpatient visits. OS was calculated from the date of operation until the date of death from any cause or the last follow-up date for live patients. The latest follow-up date was January 31, 2022.

Statistical analysis

Depend on the normality of distribution, continuous variables were presented as the mean ± standard deviation (SD) and compared using the Student’s \( t \)-test, or median (p25–p75) and compared using the Mann-Whitney \( U \)-test or Kruskal-Wallis test. While categorical data were expressed as numbers (percentages), using Chi-squared or Fisher’s exact
**TABLE 1** Patient characteristics according to postoperative skeletal muscle mass loss.

|                     | Total (n = 506) | T12 SMI loss | P-value |
|---------------------|----------------|-------------|---------|
|                     | ≥5% (n = 98)   | <5% (n = 408)|         |
| Age, years          | 64.5 [59–70]^a| 65 [60.75–70]| 64 [58–69]| 0.228 |
| Gender, male        | 384 (75.9)^b  | 77 (78.6)   | 307 (75.2)| 0.489 |
| **Comorbidities**   |               |             |         |       |
| Hypertension        | 403 (79.6)    | 80 (81.6)   | 323 (79.2)| 0.586 |
| Diabetes            | 222 (43.9)    | 49 (50.0)   | 173 (42.4)| 0.173 |
| Previous MI         | 35 (6.9)      | 7 (7.1)     | 28 (6.9)  | 0.922 |
| Cerebrovascular disease | 75 (14.8)   | 15 (15.3)   | 60 (14.7) | 0.881 |
| Tobacco use, yes    | 201 (39.7)    | 43 (43.9)   | 158 (38.7)| 0.349 |
| Alcohol use, yes    | 91 (18.0)     | 21 (21.4)   | 70 (17.2) | 0.323 |
| **Laboratory data** |               |             |         |       |
| C-reactive protein, mg/L | 3.17 [3.02–5.62] | 3.17 [3.02–6.53] | 3.17 [3.02–5.11] | 0.751 |
| White blood cells, × 10^9/L | 6.66 [5.39–8.06] | 7.06 [5.82–8.37] | 6.50 [5.32–7.99] | 0.020* |
| Red blood cells, × 10^12/L | 4.33 [3.97–4.73] | 4.26 [3.96–4.67] | 4.36 [3.97–4.75] | 0.180 |
| Hemoglobin, g/L     | 131 [119.75–143] | 129 [118–141] | 131.5 [120–144]| 0.175 |
| NLR                  | 2.36 [1.72–3.41] | 2.20 [1.59–3.44] | 2.18 [1.75–3.40] | 0.199 |
| Albumin, g/L        | 41 [38.98–44] | 41 [38–43] | 41 [39–44] | 0.331 |
| BUN, µmol/L         | 5.81 [4.78–7.08] | 6.00 [4.35–7.53] | 5.80 [4.83–6.98] | 0.929 |
| Creatinine, µmol/L  | 76.00 [64.28–90.53] | 77.95 [63.95–98.03] | 75.65 [64.35–98.99] | 0.219 |
| BMI, kg/m^2         | 24.69 [22.86–26.95] | 24.01 [22.48–26.05] | 24.91 [22.91–27.05] | 0.035* |
| Preoperative T12 SMI, cm^2/m^2 | 32.56 [28.83–37.00] | 30.55 [25.92–34.89] | 33.31 [29.49–37.93] | <0.001* |
| Postoperative T12 SMI, cm^2/m^2 | 32.56 [28.83–37.00] | 30.55 [25.92–34.89] | 33.31 [29.49–37.93] | <0.001* |
| PNI                  | 0.644          |             |         |       |
| >45                  | 421 (83.2)     | 80 (81.6)   | 341 (83.6) | 0.073 |
| ≤45                  | 85 (16.8)      | 18 (18.4)   | 67 (16.4)  |         |
| GNRI                 |               |             |         |       |
| >98                  | 447 (88.3)     | 82 (83.7)   | 365 (89.5) | 0.445 |
| 92–98                | 38 (7.5)       | 12 (12.2)   | 26 (64.6)  |         |
| 82 to <92           | 17 (3.4)       | 2 (2.0)    | 15 (3.7)       |         |
| ≤82                 | 4 (0.8)        | 2 (2.0)    | 2 (0.5)       |         |
| LVEF, %              | 60 [55–64]     | 60 [48–63.25] | 60 [56–64] | 0.045* |
| NYHA class 4        | 95 (18.8)      | 21 (21.4)   | 74 (18.1)  | 0.454 |
| EuroSCORE II, %     | 1.66 [1.30–2.28] | 1.91 [1.30–2.72] | 1.63 [1.30–2.21] | 0.023* |
| **Surgical details**|               |             |         |       |
| Surgical type       |               |             |         | 0.405 |
| Off-pump CABG       | 163 (32.2)     | 26 (26.5)   | 137 (33.6) |         |
| On-pump CABG        | 294 (58.1)     | 62 (63.3)   | 232 (56.9) |         |
| CABG + valve        | 49 (9.7)       | 10 (10.2)   | 39 (9.6)   |         |
| Use of LIMA         | 249 (49.2)     | 43 (43.9)   | 206 (50.5) | 0.240 |
| Number of bypassed vessels | 0.361          |             |         |       |
| 1                   | 41 (8.1)       | 12 (12.2)   | 29 (7.1)   |         |
| 2                   | 55 (10.9)      | 11 (11.2)   | 44 (10.8)  |         |
| 3                   | 154 (30.4)     | 26 (26.5)   | 128 (31.4) |         |
| 4 or more           | 256 (50.6)     | 49 (50.0)   | 207 (50.7) |         |
| Operative time, min | 220 [191–248.25] | 218.5 [191.5–247] | 220 [191–249] | 0.788 |
| CPR time, min       | 65.5 [0–89]    | 68.5 [0–88.75] | 64.5 [0–89] | 0.306 |
| Postoperative complications | 236 (46.6) | 51 (52.0)   | 185 (45.3) | 0.233 |
| Severe complications | 189 (37.4)     | 40 (40.8)   | 149 (36.5) | 0.430 |
| Postoperative hospital stays, days | 10 [9–13] | 10.5 [9–15] | 10 [8–13] | 0.045* |

SMI, skeletal muscle index; MI, myocardial infarction; NLR, neutrophil-to-lymphocyte ratio; BUN, blood urea nitrogen; BMI, body mass index; PNI, prognostic nutritional index; GNRI, geriatric nutritional risk index; LVEF, left ventricular ejection; NYHA, New York Heart Association; EuroSCORE II, European System for Cardiac Operative Risk Evaluation II; CABG, coronary artery bypass grafting; LIMA, left internal mammary artery; CPR, cardiopulmonary bypass.

^aMedian [p25–p75], all such values.
^bNumber (percentage), all such values.
*Statistically significant (P < 0.05).
test for comparison. Univariate Cox regression analysis was performed to determine probable risk factors of OS. Factors with $P < 0.10$ were included in the multivariate Cox analysis by a backward stepwise selection methodology. Kaplan-Meier curves and Cox proportional hazards model were used to analyze long-term survival. The variables screened by multivariate Cox regression were incorporated to develop a nomogram for OS prediction. Random resampling of the study population with a 75% ratio was performed to simulate outsource validation cohort. C-index, the area under receiver operating characteristic curve (AUC) and calibration curve were performed to evaluate the discriminative ability and predictive accuracy of the novel nomogram. All tests were two-sided and $P < 0.05$ was regarded as statistically significant. All statistical analysis was conducted by SPSS software version 26.0 (Armonk, NY, United States) and R software version 4.1.3 (Vienna, Austria).

Results

Characteristics of the patients

Initially, 548 patients underwent CABG via midline sternotomy met the inclusion criteria. And excluding unavailable postoperative chest CT scans in 42 patients, a total of 506 patients were finally analyzed in our study. The patient flow chart was shown in Figure 1.

Patient characteristics were presented in Table 1. Based on the preoperative and postoperative chest CT scans of each patient, 98 (19.37%) patients demonstrated T12 SMI loss $\geq 5\%$, while 408 (80.63%) patients had T12 SMI loss $< 5\%$. The two
groups were comparable in terms of age, gender, comorbidities, C-reactive protein, red blood cells, hemoglobin, neutrophil-to-lymphocyte ratio (NLR), albumin, blood urea nitrogen (BUN), creatinine, preoperative T12 SMI, surgical details, and postoperative complications. However, ≥ 5% T12 SMI loss was associated with lower body mass index (BMI) \((P = 0.035)\) and postoperative T12 SMI \((P < 0.001)\). In contrast, patients with T12 SMI ≥ 5% loss had higher white blood cells \((P = 0.020)\). Although the left ventricular ejection (LVEF) and postoperative hospital stays of two groups were quite close, patients who exhibited ≥ 5% T12 SMI loss had higher LVEF \((P = 0.045)\) and longer postoperative hospital stays \((P = 0.045)\). For the risk score of cardiac surgery, EuroSCORE II score was higher in T12 SMI loss ≥ 5% group than in T12 SMI loss < 5% group \((P = 0.023)\).

The influence of various clinical factors on postoperative skeletal muscle index change

As shown in Supplementary Table 1, preoperative low SMI \((P = 0.003)\), BMI \((P = 0.023)\), LVEF \((P = 0.013)\), hypoproteinemia \((P < 0.001)\), PNI \((P < 0.001)\), and GNRI \((P = 0.013)\) may be essential preoperative factors.
affecting postoperative SMI change. However, postoperative complications did not affect postoperative %T12 SMI-change. In addition, of the 506 patients, 190 (37.5%) patients received doctor’s recommendation to take ONS after surgery. The median of %T12 SMI-change was −0.67 [−4.15–3.44]% and 1.12 [−3.82–4.54]% for patients without and with ONS, respectively (Figure 2). And there was significant difference in %T12 SMI-change between the two groups (P = 0.015).

Relationship between postoperative skeletal muscle index loss and overall survival

During a median of 3.38 years follow-up, 43 (8.5%) patients died. The survival curves demonstrated that patients with T12 SMI ≥ 5% loss had a significantly worse OS relative to those with < 5% T12 SMI loss (Figure 3, Log-rank: P < 0.0001). Univariate and multivariate Cox regression analyses for OS were presented in Table 2. In the multivariate analysis, Preoperative low SMI (P = 0.003) and %T12 SMI-change (P < 0.001) were independent prognostic factor for OS in patients underwent CABG, alongside age (P = 0.010) and LVEF ≤ 50% (P = 0.033).

Construction and validation of the prognostic nomogram

Based on the results of multivariate Cox regression analysis, four independent predictors were integrated to developed a novel nomogram for predicting OS (Figure 4). Each variable has a score on the point scale, and the estimated probability of 1-, 2-,
and 3-year OS could easily be obtained by adding the total score and placing it on the total score scale. Patient characteristics in validation cohort were shown in Supplementary Table 2. The C-index for overall and validation cohort were 0.77 (95% CI: 0.69-0.86) and 0.82 (95% CI: 0.72-0.92), respectively. Furthermore, the nomogram yielded AUC values of 0.862, 0.819, 0.802 in the overall population and 0.856, 0.833, 0.863 in the validation cohort for predicting OS rates at 1, 2 and 3 years (Figure 5). The calibration curve of the nomogram for the survival probability at 1 and 2 years demonstrated good agreement between prediction and observation in the overall population and the validation cohort (Figure 6). In addition, when compared with EuroSCORE II, the novel nomogram with body composition-related parameters demonstrated higher predictive ability of long-term survival (Figure 7).

**Discussion**

To our knowledge, this is the first study to investigate the relationship between postoperative skeletal muscle loss and prognosis in patients underwent CABG. In the present study, we have demonstrated that about 20% of these patients have T12 SMI loss ≥ 5% 3 months after CABG, and postoperative ONS could rescue T12 SMI loss. Furthermore, we have presented evidence suggesting that %T12 SMI-change is an independent risk factor for OS of CABG. A nomogram incorporating %T12 SMI-change as well as the parameters such as age, preoperative low SMI, LVEF ≤ 50% was developed. Importantly, compared with EuroSCORE II, our novel nomogram showed stronger prediction efficiency for long-term outcomes.

Surgical trauma is frequently accompanied with hyperglycemia, accelerated systemic protein catabolism...
Recent studies have investigated the impact of preoperative skeletal muscle loss on survival in patients receiving CABG. In our previous study, preoperative sarcopenia was proved to be an independent risk factor for postoperative complications and OS of CABG (10). Actually, postoperative skeletal muscle loss not only leads to a decrease in postoperative quality of life (18), but also causes decreased exercise capacity and impaired respiratory function (35). Therefore, comparing with preoperative sarcopenia, postoperative skeletal muscle loss is more sensitive for worse long-term prognosis, as it reflects the response to the surgical trauma and stress of patients. In this study, patients with postoperative T12 SMI loss ≥ 5% were more likely to have adverse OS (Figure 3). Multivariate Cox analysis demonstrated that preoperative low SMI, %T12 SMI-change, age and LVEF ≤ 50% remain independent risk factors of OS. For patients underwent CABG, reduced LVEF is frequently associated with ischemic cardiomyopathy and increases the risk of postoperative adverse events (36). Thus, we incorporated all four independent risk factors into an innovative nomogram for predicting long-term survival in CABG patients.

EuroSCORE II, the most commonly used risk assessment tool, has been shown to be effective in predicting postoperative risk in patients underwent cardiac surgery (37, 38). And EuroSCORE II is mainly based on clinical characteristics, surgical factors, and echocardiographic findings (39). In addition to the above factors, inflammation, left ventricular systolic dysfunction, nutritional status, and body composition can also affect patient outcomes. Even though EuroSCORE II is accurate in predicting short-term outcomes, its performance fades for mortality at follow-up longer than 30 days (40, 41). Therefore, it is necessary to develop a new risk stratification tool to predict long-term clinical outcomes. In this study, we exploited a nomogram for predicting OS in CABG patients, which showed favorable discrimination with AUC values consistently more than 0.8 and significantly higher than EuroSCORE II. The calibration curve of our nomogram for the survival probability at 1- and 2-year revealed good agreement between predicted and actual OS.

Exercise-based cardiac rehabilitation has been strongly recommended as an important adjunctive therapy after CABG in recent years (42, 43). Previous studies have demonstrated that exercise rehabilitation training can reduce muscle strength loss and improve postoperative quality of life after CABG (44–46). Whereas, some factors, such as postoperative pain, the risk of exercise, and the lack of local physiotherapy services make exercise-based cardiac rehabilitation programs less effective. The use of ONS can provide supplementary energy and nutrition in addition to normal food to improve energy expenditure from surgical trauma. Multiple previous studies have demonstrated that ONS can benefit patients by reducing postoperative skeletal muscle loss in many surgical procedures (47–49). As expected, ONS alleviated postoperative fluid retention.
SMI loss in patients underwent CABG in our study, which adds a new strategy for cardiac rehabilitation programs. And as a reflection of systemic nutritional status, changes in SMI can be considered for evaluating the effects of ONS and guiding dietary recommendations.

There are some limitations to the present study. This is a single-center study and its findings need to be validated in international multi-center studies. Nonetheless, the present study still presents a large impact of postoperative SMI loss on OS. Else, due to the retrospective design of the study cohort, we only investigated changes in SMI in this study, and our future prospective studies intend to focus on the changes in skeletal muscle density and function after cardiac surgery. Finally, we only found that the application of ONS was associated with improved postoperative skeletal muscle loss in this study, and we are conducting a prospective study to further investigate the effect of ONS on clinical outcomes.

Conclusion

Postoperative SMI loss has an effective prognostic influence on long-term survival after CABG. ONS may be considered for patients underwent cardiac surgery to reduce skeletal muscle degradation and improve outcomes. The nomogram incorporating changes in SMI performs well in survival prediction.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethics Committee of Shanghai Tenth People’s Hospital. The patients/participants provided their written informed consent to participate in this study.

Author contributions

Z-LS, W-FZ, X-LY, and ZY designed the study. PZ, W-ZC, W-XD, W-HC, and FL collected the data. ZL did the analysis and interpretation of data. Z-LS wrote the article. ZY revised the article and took the decision to submit the article for publication. All authors gave final approval and agreed to take responsibility for all aspects of this work to ensuring integrity and accuracy.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2022.970729/full#supplementary-material

References

1. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics-2022 update: a report from the American heart association. Circulation. (2022) 145:e153–639. doi: 10.1161/CIR.0000000000001052
2. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors. 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. (2020) 76:2982–3021. doi: 10.1016/j.jacc.2020.11.010
3. Takahashi K, Serruys PW, Gao C, Ono M, Wang R, Thuijs D, et al. Ten-Year All-Cause death according to completeness of revascularization in patients with three-vessel disease or left main coronary artery disease: insights from the SYNTAX extended survival study. Circulation. (2021) 144:96–109. doi: 10.1161/CIRCULATIONAHA.120.046289
4. Doenst T, Haverich A, Serruys PW, Bonow RO, Kappetein P, Falk V, et al. PCI and CABG for treating stable coronary artery disease: JACC review topic of the week. J Am Coll Cardiol. (2019) 73:964–76. doi: 10.1016/j.jacc.2018.11.053
5. Poßl L, Thielmann M, Cymorek S, Nagele F, Hirsch J, Gruber M, et al. Impact of myocardial injury after coronary artery bypass grafting on long-term prognosis. 
Eur Heart J. (2022) 43:2407–17. doi: 10.1093/eurheartj/ehac054

6. Thuijs D, Davierwala P, Mileovic M, Deo SV, Noack T, Kappetein AP, et al. Long-term survival after coronary bypass surgery with multiple versus single arterial grafts. 
Eur J Cardiothorac Surg. (2022) 61:925–33. doi: 10.1093/ejcts/ezab392

7. Teman NR, Hawkins RB, Charles EJ, Mehaffey AM, Quader MA, et al. Minimally invasive vs open coronary surgery: a multi-institutional analysis. 
Ann Thorac Surg. (2021) 111:1478–84. doi: 10.1016/j.athoracsur.2020.06.136

8. Squiers JJ, Schaffer JM, Banwait JK, Ryan WH, Mack MJ, DiMaio JM. Long-term survival after on-pump and off-pump coronary artery bypass grafting. 
Ann Thorac Surg. (2021) 113:1943–52. doi: 10.1016/j.athoracsur.2021.07.037

9. Gaudino M, Audioso K, Rahouma M, Chadow D, Cancello G, Soletti GJ, et al. Comparison of long-term clinical outcomes of skeletonized vs pedicled internal thoracic artery harvesting techniques in the arterial revascularization trial. 
JAMA Cardiol. (2021) 6:1380–86. doi: 10.1001/jamacardio.2021.3666

10. Shen ZL, Liu Z, Zang WF, Zhang P, Zou HB, Dong WX, et al. Thoracic sarcopenia predicts clinical outcomes in patients underwent coronary artery bypass grafting: a 4-year cohort study. 
Asian J Surg. (2022). doi: 10.1016/j.asjsur.2022.03.096 [Epub ahead print]

11. Hansen D, Linzen L, Verboven K, Hendriks M, Rummens JL, van Erum M, et al. Magnitude of muscle wasting early after on-pump coronary bypass graft surgery and exploration of aetiology. 
Exp Physiol. (2015) 100:818–28. doi: 10.1113/EP085053

12. Sudek P, Munoz F, Marchand F, Chapurlat R, Delmas PD. Rapid loss of appendicular skeletal muscle mass is associated with higher all-cause mortality in older men: the prospective MINOS study. 
Am J Clin Nutr. (2010) 91:1227–36. doi: 10.3944/ajcn.2009.28256

13. Cossa AP, Sueda S, Piu P, Orecchioni M, Bazzu G, Padua G, et al. Do on- and off-pump coronary bypass surgery differ on perioperative peripheral tissue metabolism? 
Minerva Anestesiol. (2012) 78:26–33.

14. van Gessel RJ, Baggerman MR, de van Dijk MCG. Metabolic aspects of muscle wasting during critical illness. 
Curr Opin Clin Nutr Metab Care. (2022) 23:10–5. doi: 10.1097/MCN.0000000000001628

15. Okamura H, Kimura N, Mieno M, Yuni K, Yamaguchi A. Preoperative sarcopenia is associated with late mortality after off-pump coronary bypass grafting. 
Eur J Cardiothorac Surg. (2020) 58:121–9. doi: 10.1093/ejcts/ezz378

16. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. 
Ann Surg. (2004) 230:187–96. doi: 10.1097/01.sla.0000131811.13312.3a

17. Dervinac BA, Holcombe SA, Ross BE, Wang NC, So GL, Wang SC. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. 
Sick Sci. (2018) 8:11369. doi: 10.4172/1915-1169.10002825-2

18. van Venrooij LM, Verberne HJ, de Vos R, Borgmeijer-Hoelen MM, van Lenten PA, de Mol RA. Postoperative loss of skeletal muscle mass, complications and quality of life in patients undergoing cardiac surgery. 
Nutrition. (2012) 28:40–5. doi: 10.1016/j.nut.2011.02.007

19. Tan S, Zhaung Q, Zhang Z, Li S, Xu J, Wang J, et al. Postoperative loss of skeletal muscle mass predicts poor survival after gastric cancer surgery. 
Front Nutr. (2022) 9:794576. doi: 10.3389/fnut.2022.794576

20. Lee J, Jin JB, Wu MH, Chang CL, Jan YT, Chen YJ. Muscle loss after chemoradiotherapy as a biomarker of distant failures in locally advanced cervical cancer. 
Cancers (2020) 12:3. doi: 10.3390/cancers12030595

21. Huang CY, Yang YC, Chen TC, Chen JR, Chen YJ, Wu MH, et al. Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer. 
J Cachexia Sarcopenia Muscle. (2020) 11:534–46. doi: 10.1007/s12275-020-01065-1

22. Schircker T, Lattermann R. Perioperative catabolism. Can J Anaesth. (2015) 62:182–93. doi: 10.1007/s12320-014-0124-7

23. Weinmann A, Braga M, Carli F, Higashiguchi T, Hubner M, Klek S, et al. ESPEN practical guideline: clinical nutrition in surgery. 
Clin Nutr. (2021) 40:4745–61. doi: 10.1016/j.clnu.2021.03.031

24. Caso G, Vossenwinkel JA, Garlock PJ, Barry MK, Billinger TV, McNaul MA. Altered protein metabolism following coronary artery bypass graft (CABG) surgery. 
Clin Sci. (2008) 114:339–46. doi: 10.1042/CS20070027

25. Wolfe RR. The underappreciated role of muscle in health and disease. 
Am J Clin Nutr. (2006) 84:475–82. doi: 10.1093/ajcn/84.3.475
45. Dos Santos TD, Pereira SN, Portela LOC, Cardoso DM, Lago PD, Dos Santos Guarda N, et al. Moderate-to-high intensity inspiratory muscle training improves the effects of combined training on exercise capacity in patients after coronary artery bypass graft surgery: a randomized clinical trial. *Int J Cardiol.* (2019) 279:40–6. doi: 10.1016/j.ijcard.2018.12.013

46. Nishitani M, Shimada K, Masaki M, Sunayama S, Kume A, Fukao K, et al. Effect of cardiac rehabilitation on muscle mass, muscle strength, and exercise tolerance in diabetic patients after coronary artery bypass grafting. *J Cardiol.* (2013) 61:216–21. doi: 10.1016/j.jjcc.2012.11.004

47. Tan S, Meng Q, Jiang Y, Zhuang Q, Xi Q, Xu J, et al. Impact of oral nutritional supplements in post-discharge patients at nutritional risk following colorectal cancer surgery: a randomised clinical trial. *Clin Nutr.* (2021) 40:47–53. doi: 10.1016/j.clnu.2020.05.038

48. Malafarina V, Uriz-Otano F, Malafarina C, Martinez JA, Zulet MA. Effectiveness of nutritional supplementation on sarcopenia and recovery in hip fracture patients. A multi-centre randomized trial. *Maturitas.* (2017) 101:42–50. doi: 10.1016/j.maturitas.2017.04.010

49. Cereda E, Cappello S, Colombo S, Rlero C, Imarisio L, Turr A, et al. Nutritional counseling with or without systematic use of oral nutritional supplements in head and neck cancer patients undergoing radiotherapy. *Radiother Oncol.* (2018) 126:81–8. doi: 10.1016/j.radonc.2017.10.015